

# 제24회 대한혈액학회 AML/MDS 연구회 추계 심포지엄

일자 | 2019년 10월 5일 (토요일)

장소 | 서울대학교병원 의학혁신센터 서성환연구홀

09:30-09:55

Registration

09:55-10:00

Opening remark

## Evidence-based treatment approaches for MDS and AML

좌장 장준호 (성균관의대)

10:00-10:30

Updated usage of NGS in myeloid leukemia

김명신 (가톨릭의대)

10:30-11:00

Treatment approaches according to risk groups in AML patients with targetable molecules

최윤숙 (울산의대)

11:00-11:30

Relevant targets in pediatric AML and potential for therapy

이재욱 (가톨릭의대)

11:30-12:00

MDS therapeutics beyond hypomethylating agent

김성용 (건국의대)

12:00-13:20

Lunch

## 국내 연구

### Elderly AML

Moderator 최철원 (고려의대)

13:20-13:40

A multicenter, retrospective analysis of elderly patients with acute myeloid leukemia who were treated with decitabine (Oncotarget 2018;9:6607)

이준호 (중앙의대)

13:40-14:00

Comparison of the modified low-dose cytarabine and etoposide with decitabine therapy for elderly acute myeloid leukemia patients unfit for intensive chemotherapy (Oncotarget 2017;9:5823)

조병식 (가톨릭의대)

14:00-14:20

Decitabine versus intensive chemotherapy for elderly patients with newly diagnosed acute myeloid leukemia (Clin Lymphoma Myeloma Leuk. 2019;19:290)

최은지 (울산의대)

### Pediatric AML

Moderator 강형진 (서울의대)

14:20-14:40

Unrelated donor hematopoietic stem cell transplantation for pediatric de novo acute myeloid leukemia with intermediate- or high-risk cytogenetics (Pediatr Transplant 2019;23:e13397)

이은상 (고려의대)

14:40-14:55

Coffee break

## 연구회 임상연구

### 연구 보고

14:55-15:00

연구회 연구 전반 진행 상황 update 보고

김 혁 (가천의대)

### 신규 연구

15:00-15:25

Post-transplantation strategies for high risk AML/MDS

손상균 (경북의대)

15:25-15:40

Dose-adjusted SALvage chemotheraPy Plus FLT3-inHibitor Quizartinib In RElapsed/refractory acute myeloid leukemia with mutated FLT3-ITD/TKD (SAPPHIRE-Q)

김 혁 (가천의대)

15:40

Closing remark



The Korean Society of Hematology



AML/MDS  
WORKING PARTY  
The Korean Society of Hematology